BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...about $1 million. Only one patient, in Germany, was ever reimbursed. UniQure’s roots lie in Amsterdam Molecular Therapeutics Holding N.V....
BioCentury | Aug 20, 2019
Company News

Management tracks: uniQure, Provention, Anaptys, FDA and more

...be eliminated. van Deventer is an operating partner at Forbion Partners and co-founded uniQure's predecessor Amsterdam Molecular...
BioCentury | Jun 18, 2019
Company News

Latest twist in uniQure’s tale: possible sale

...$81.14, and a market cap of about $3.1 billion. uniQure N.V. (NASDAQ:QURE), formerly known as Amsterdam Molecular...
BioCentury | Nov 21, 2014
Clinical News

St. Jude, UCL gene therapy cuts bleeding in hemo B trial

...and Spark's AAV8-hFIX19 are all in Phase I/II testing to treat hemophilia B. uniQure predecessor Amsterdam Molecular...
BioCentury | Feb 10, 2014
Finance

uniQure completes comeback

...uniQure's first foray into the public markets came in 2007 when the company, then called Amsterdam Molecular...
...two negative decisions for Glybera from EMA 's CHMP, management and investors decided to take Amsterdam Molecular...
BioCentury | Sep 2, 2013
Clinical News

AAV2-GDNF: Phase I started

...open-label, dose-escalation Phase I trial to evaluate AAV2-GDNF in about 24 PD patients. Last year, Amsterdam Molecular...
BioCentury | Feb 11, 2013
Company News

uniQure B.V., Xenon deal

...Xenon said it received an undisclosed milestone payment from uniQure under a 2001 deal granting Amsterdam Molecular Therapeutics Holding N.V....
BioCentury | Nov 5, 2012
Clinical News

Glybera alipogene tiparvovec regulatory update

...FDA for Glybera by next quarter. The approval comes nearly 3 years after uniQure's predecessor, Amsterdam Molecular Therapeutics Holding N.V....
...CHMP reversed its prior negative opinions and recommended approval of Glybera (see BioCentury, July 23). Amsterdam Molecular...
BioCentury | Nov 3, 2012
Top Story

EC approves gene therapy Glybera

...FDA for Glybera by next quarter. The approval comes nearly three years after uniQure's predecessor, Amsterdam Molecular Therapeutics Holding N.V....
...to consider the product in a restricted patient population with severe or multiple pancreatitis attacks. Amsterdam Molecular...
BioCentury | Jul 30, 2012
Regulation

Persistence pays off

...the process cost uniQure's publicly traded predecessor nearly all its institutional investors and ultimately forced Amsterdam Molecular Therapeutics Holding N.V....
...is a clear signal of LPL enzyme functionality. van Deventer, formerly CSO and CEO of Amsterdam Molecular Therapeutics Holding N.V....
Items per page:
1 - 10 of 139
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...about $1 million. Only one patient, in Germany, was ever reimbursed. UniQure’s roots lie in Amsterdam Molecular Therapeutics Holding N.V....
BioCentury | Aug 20, 2019
Company News

Management tracks: uniQure, Provention, Anaptys, FDA and more

...be eliminated. van Deventer is an operating partner at Forbion Partners and co-founded uniQure's predecessor Amsterdam Molecular...
BioCentury | Jun 18, 2019
Company News

Latest twist in uniQure’s tale: possible sale

...$81.14, and a market cap of about $3.1 billion. uniQure N.V. (NASDAQ:QURE), formerly known as Amsterdam Molecular...
BioCentury | Nov 21, 2014
Clinical News

St. Jude, UCL gene therapy cuts bleeding in hemo B trial

...and Spark's AAV8-hFIX19 are all in Phase I/II testing to treat hemophilia B. uniQure predecessor Amsterdam Molecular...
BioCentury | Feb 10, 2014
Finance

uniQure completes comeback

...uniQure's first foray into the public markets came in 2007 when the company, then called Amsterdam Molecular...
...two negative decisions for Glybera from EMA 's CHMP, management and investors decided to take Amsterdam Molecular...
BioCentury | Sep 2, 2013
Clinical News

AAV2-GDNF: Phase I started

...open-label, dose-escalation Phase I trial to evaluate AAV2-GDNF in about 24 PD patients. Last year, Amsterdam Molecular...
BioCentury | Feb 11, 2013
Company News

uniQure B.V., Xenon deal

...Xenon said it received an undisclosed milestone payment from uniQure under a 2001 deal granting Amsterdam Molecular Therapeutics Holding N.V....
BioCentury | Nov 5, 2012
Clinical News

Glybera alipogene tiparvovec regulatory update

...FDA for Glybera by next quarter. The approval comes nearly 3 years after uniQure's predecessor, Amsterdam Molecular Therapeutics Holding N.V....
...CHMP reversed its prior negative opinions and recommended approval of Glybera (see BioCentury, July 23). Amsterdam Molecular...
BioCentury | Nov 3, 2012
Top Story

EC approves gene therapy Glybera

...FDA for Glybera by next quarter. The approval comes nearly three years after uniQure's predecessor, Amsterdam Molecular Therapeutics Holding N.V....
...to consider the product in a restricted patient population with severe or multiple pancreatitis attacks. Amsterdam Molecular...
BioCentury | Jul 30, 2012
Regulation

Persistence pays off

...the process cost uniQure's publicly traded predecessor nearly all its institutional investors and ultimately forced Amsterdam Molecular Therapeutics Holding N.V....
...is a clear signal of LPL enzyme functionality. van Deventer, formerly CSO and CEO of Amsterdam Molecular Therapeutics Holding N.V....
Items per page:
1 - 10 of 139